I think they'll be able to collect all the DMOAD data they need...

I think they'll be able to collect all the DMOAD data they need from the current set of trials, but are using 008 to both inform secondary endpoints for the P3 trials and to demonstrate an association between the biomarkers in the synovial fluid to those in serum, as well as to the MRI and pain and function results.

It'll be very difficult to engage in a larger trial to collect synovial fluid from a lot more participants. Instead, if PAR find that changes in biomarkers in synovial fluid correspond to similar changes in serum, then this will be indicative of changes taking place in the synovium. It will also enable only serum to be assessed for biomarker changes in subsequent studies. I think we are already collecting serum as part of the P3 trials, so will just have to add on some biomarker secondary endpoints once the results for 008 are known.